Therefore, it has been hypothesized that selectively inhibiting PARP1 would reduce PARPi toxicity associated with PARP2 inhibition while improving synthetic lethality in HRD cancers and subsequently improving the efficacy of PARPi treatments. This evidence concerns the gene PARP1 and cancer.